Neuraxis (NRXS) Cost of Revenue (2022 - 2025)
Neuraxis (NRXS) posted Cost of Revenue of $1.9 million for Q4 2025, up 143.75% sequentially from $762548.0 in Q3 2025, and up 1669.31% YoY from $105053.0 in Q4 2024.
Neuraxis (NRXS) Cost of Revenue (2022 - 2025) Analysis & Trends
Neuraxis has reported Cost of Revenue for 4 years, with the latest figure at $1.9 million in Q4 2025.
- Quarterly Cost of Revenue rose 1669.31% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.9 million (up 395.3% YoY) and the FY2025 annual result came in at $2.3 million, up 529.82% from the prior year.
- Cost of Revenue rose to $1.9 million in Q4 2025 per NRXS's latest filing, from $762548.0 in the prior quarter.
- Over five years, Cost of Revenue peaked at $1.9 million in Q4 2025 and troughed at $62274.0 in Q2 2024.
- A 4-year average of $268460.9 and a median of $81589.0 in 2022 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2024 and 2025: Cost of Revenue retreated 25.85% in 2024, then surged 1669.31% in 2025.
- Over 4 years, Cost of Revenue stood at $65991.0 in 2022, then increased by 10.07% to $72636.0 in 2023, then jumped by 44.63% to $105053.0 in 2024, then soared by 1669.31% to $1.9 million in 2025.
- According to Business Quant data, Cost of Revenue over the past three periods registered $1.9 million, $762548.0, and $146643.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 298.26 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 67.21 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 387.98 Mn |
| 10 | Neuraxis | 75.51 Mn | 67.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.86 Mn |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | 762,548.00 |
| Sep 30, 2025 | 762,548.00 |
| Jun 30, 2025 | 146,643.00 |
| Jun 30, 2025 | 146,643.00 |
| Mar 31, 2025 | 133,954.00 |
| Mar 31, 2025 | 133,954.00 |
| Dec 31, 2024 | 105,053.00 |
| Dec 31, 2024 | 105,053.00 |
| Sep 30, 2024 | 338,523.00 |
| Sep 30, 2024 | 338,523.00 |
| Jun 30, 2024 | 62,274.00 |
| Jun 30, 2024 | 62,274.00 |
| Mar 31, 2024 | 80,030.00 |
| Mar 31, 2024 | 80,030.00 |
| Dec 31, 2023 | 72,636.00 |
| Dec 31, 2023 | 72,636.00 |
| Sep 30, 2023 | 64,210.00 |
| Sep 30, 2023 | 64,210.00 |